Phase 1 study of ERAS-0015, a RAS inhibitor small molecule.

This open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of ERAS-0015 administered alone or with additional investigational agents in patients with advanced or metastatic solid tumors harboring RAS mutations. Enrolling patients at Fairfax and sponsored by Erasca, Inc., the study aims to optimize dosing in this first-in-human trial.